In a 17‑week pregnant G2P1 woman with a prior spontaneous preterm delivery at 35 weeks, should she receive progesterone therapy?

Yes, she should be started on progesterone therapy immediately.

Based on established guidelines, this patient with a singleton pregnancy and prior spontaneous preterm birth at 35 weeks should receive 17-alpha-hydroxyprogesterone caproate (17P) 250 mg intramuscularly weekly, starting now (ideally between 16-20 weeks) and continuing until 36 weeks of gestation 1.

Clinical Reasoning

The Society for Maternal-Fetal Medicine (SMFM) guidelines are unequivocal: singletons with prior spontaneous preterm birth (SPTB) should receive 17P 250 mg IM weekly from 16-20 weeks until 36 weeks 1. This patient at 17 weeks fits this indication perfectly.

Evidence Supporting This Recommendation

The landmark 2003 trial by Meis et al. demonstrated that weekly 17P injections resulted in:

• 36.3% vs 54.9% delivery rate before 37 weeks (relative risk 0.66) 2
• Significant reductions in delivery before 35 weeks (20.6% vs 30.7%) and before 32 weeks (11.4% vs 19.6%)
• Lower rates of necrotizing enterocolitis, intraventricular hemorrhage, and need for supplemental oxygen in infants

Importantly, a 2005 analysis showed that 17P is most effective when the prior preterm birth occurred before 34 weeks, with women delivering at significantly more advanced gestational ages (median 37.3 vs 35.4 weeks for those with prior delivery at 20-27.9 weeks) 3. While this patient's prior delivery at 35 weeks represents a "late preterm" birth, she still qualifies for and should receive treatment.

The Vaginal Progesterone Controversy

Do NOT use vaginal progesterone as first-line therapy in this patient based solely on her history of prior preterm birth. The evidence is clear on this point:

• Multiple large trials (OPPTIMUM, PROGRESS) showed no benefit of vaginal progesterone in women with prior SPTB when used without cervical length criteria 4, 5
• The 2017 SMFM statement explicitly reaffirmed that vaginal progesterone has not been adequately proven to decrease recurrent PTB in women with prior SPTB 6
• Recent 2023 evidence-based recommendations state there is no convincing evidence supporting VP in singleton gestations based solely on history of SPTB 7

The Exception: Short Cervix on Ultrasound

If serial transvaginal ultrasound cervical length screening reveals a cervix <25 mm before 24 weeks, the management changes:

1. Continue the 17P (do not stop it)
2. Consider adding vaginal progesterone (90-mg gel or 200-mg suppository daily) 1, 8
3. Consider cerclage placement for very short cervix (<15 mm) 1

The evidence shows that in women with prior SPTB who develop cervical shortening to ≤25 mm, there is additional benefit from vaginal progesterone, with meta-analysis showing:

• 46% reduction in PTB <33 weeks (RR 0.54)
• 59% reduction in composite neonatal morbidity and mortality (RR 0.41) 1

Practical Implementation

Start now:

• 17P 250 mg IM weekly
• Begin at current gestational age (17 weeks)
• Continue until 36 weeks or delivery

Monitor with serial cervical length screening:

• Transvaginal ultrasound cervical length every 2 weeks from 16-24 weeks
• If cervix shortens to <25 mm: add vaginal progesterone and consider cerclage
• If cervix remains ≥25 mm: continue 17P alone 1

Critical Pitfalls to Avoid

1. Do not delay treatment waiting for cervical length assessment—start 17P now based on history alone
2. Do not substitute vaginal progesterone for 17P in this patient—the evidence does not support this approach 6
3. Do not stop 17P if cervix shortens—continue it and add other interventions 1, 6
4. Do not use progesterone if this were a twin gestation—multiple gestations show no benefit from progestogens 1

The 2012 SMFM guidelines remain the standard of care, and this patient's clinical scenario fits squarely within the evidence-based indication for 17P therapy to reduce recurrent preterm birth and improve neonatal outcomes.